APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatocellular Carcinoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hepatocellular Carcinoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025197 pages

Choose your research edition.

Industry ResearchHepatocellular Carcinoma Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatocellular Carcinoma Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Hepatocellular Carcinoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatocellular Carcinoma Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatocellular Carcinoma Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hepatocellular Carcinoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatocellular Carcinoma Drug include Teva Pharmaceutical, Sun Pharmaceutical, Johnson & Johnson, Novartis, Sigma-Tau Group, Pacira, Luye Pharma, Kingond Pharm and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatocellular Carcinoma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatocellular Carcinoma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatocellular Carcinoma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatocellular Carcinoma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatocellular Carcinoma Drug Segment by Company

Teva Pharmaceutical

Sun Pharmaceutical

Johnson & Johnson

Novartis

Sigma-Tau Group

Pacira

Luye Pharma

Kingond Pharm

Gilead Sciences

Fudan-Zhangjiang

CSPC

Hepatocellular Carcinoma Drug Segment by Type

Ablation Therapy

Brachytherapy

Chemotherapy

Hepatocellular Carcinoma Drug Segment by Application

Surgical Resection

Ablation

Liver Transplantation

Hepatocellular Carcinoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatocellular Carcinoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatocellular Carcinoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatocellular Carcinoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatocellular Carcinoma Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatocellular Carcinoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hepatocellular Carcinoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hepatocellular Carcinoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hepatocellular Carcinoma Drug Industry Trends Table 2. Hepatocellular Carcinoma Drug Industry Drivers Table 3. Hepatocellular Carcinoma Drug Industry Opportunities and Challenges Table 4. Hepatocellular Carcinoma Drug Industry Restraints Table 5. Global Hepatocellular Carcinoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hepatocellular Carcinoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hepatocellular Carcinoma Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Hepatocellular Carcinoma Drug Sales Market Share by Manufacturers Table 9. Global Hepatocellular Carcinoma Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Hepatocellular Carcinoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hepatocellular Carcinoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hepatocellular Carcinoma Drug Manufacturers, Product Type & Application Table 13. Global Hepatocellular Carcinoma Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatocellular Carcinoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ablation Therapy Table 17. Major Manufacturers of Brachytherapy Table 18. Major Manufacturers of Chemotherapy Table 19. Global Hepatocellular Carcinoma Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 21. Global Hepatocellular Carcinoma Drug Sales by Type (2027-2032) & (k units) Table 22. Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2021-2026) Table 23. Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2027-2032) Table 24. Global Hepatocellular Carcinoma Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Hepatocellular Carcinoma Drug Revenue by Type (2021-2026) & (k units) Table 26. Global Hepatocellular Carcinoma Drug Revenue by Type (2027-2032) & (k units) Table 27. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2021-2026) Table 28. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Surgical Resection Table 30. Major Manufacturers of Ablation Table 31. Major Manufacturers of Liver Transplantation Table 32. Global Hepatocellular Carcinoma Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 34. Global Hepatocellular Carcinoma Drug Sales by Application (2027-2032) & (k units) Table 35. Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2021-2026) Table 36. Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2027-2032) Table 37. Global Hepatocellular Carcinoma Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Hepatocellular Carcinoma Drug Revenue by Application (2021-2026) & (k units) Table 39. Global Hepatocellular Carcinoma Drug Revenue by Application (2027-2032) & (k units) Table 40. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2021-2026) Table 41. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2027-2032) Table 42. Global Hepatocellular Carcinoma Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Hepatocellular Carcinoma Drug Sales by Region (2021-2026) & (k units) Table 44. Global Hepatocellular Carcinoma Drug Sales Market Share by Region (2021-2026) Table 45. Global Hepatocellular Carcinoma Drug Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Hepatocellular Carcinoma Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 49. North America Hepatocellular Carcinoma Drug Sales by Country (2027-2032) & (k units) Table 50. Europe Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 52. Europe Hepatocellular Carcinoma Drug Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Hepatocellular Carcinoma Drug Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2027-2032) & (k units) Table 59. Global Hepatocellular Carcinoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Hepatocellular Carcinoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Hepatocellular Carcinoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2021-2026) Table 63. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2027-2032) Table 64. Teva Pharmaceutical Company Information Table 65. Teva Pharmaceutical Business Overview Table 66. Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio Table 68. Teva Pharmaceutical Recent Development Table 69. Sun Pharmaceutical Company Information Table 70. Sun Pharmaceutical Business Overview Table 71. Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio Table 73. Sun Pharmaceutical Recent Development Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Hepatocellular Carcinoma Drug Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Novartis Hepatocellular Carcinoma Drug Product Portfolio Table 83. Novartis Recent Development Table 84. Sigma-Tau Group Company Information Table 85. Sigma-Tau Group Business Overview Table 86. Sigma-Tau Group Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sigma-Tau Group Hepatocellular Carcinoma Drug Product Portfolio Table 88. Sigma-Tau Group Recent Development Table 89. Pacira Company Information Table 90. Pacira Business Overview Table 91. Pacira Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pacira Hepatocellular Carcinoma Drug Product Portfolio Table 93. Pacira Recent Development Table 94. Luye Pharma Company Information Table 95. Luye Pharma Business Overview Table 96. Luye Pharma Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Luye Pharma Hepatocellular Carcinoma Drug Product Portfolio Table 98. Luye Pharma Recent Development Table 99. Kingond Pharm Company Information Table 100. Kingond Pharm Business Overview Table 101. Kingond Pharm Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Kingond Pharm Hepatocellular Carcinoma Drug Product Portfolio Table 103. Kingond Pharm Recent Development Table 104. Gilead Sciences Company Information Table 105. Gilead Sciences Business Overview Table 106. Gilead Sciences Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Gilead Sciences Hepatocellular Carcinoma Drug Product Portfolio Table 108. Gilead Sciences Recent Development Table 109. Fudan-Zhangjiang Company Information Table 110. Fudan-Zhangjiang Business Overview Table 111. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Portfolio Table 113. Fudan-Zhangjiang Recent Development Table 114. CSPC Company Information Table 115. CSPC Business Overview Table 116. CSPC Hepatocellular Carcinoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. CSPC Hepatocellular Carcinoma Drug Product Portfolio Table 118. CSPC Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Hepatocellular Carcinoma Drug Distributors List Table 122. Hepatocellular Carcinoma Drug Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Hepatocellular Carcinoma Drug Product Image Figure 2. Global Hepatocellular Carcinoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatocellular Carcinoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatocellular Carcinoma Drug Sales (2021-2032) & (k units) Figure 5. Global Hepatocellular Carcinoma Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hepatocellular Carcinoma Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ablation Therapy Image Figure 9. Brachytherapy Image Figure 10. Chemotherapy Image Figure 11. Global Hepatocellular Carcinoma Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Hepatocellular Carcinoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2021-2032) Figure 14. Global Hepatocellular Carcinoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Hepatocellular Carcinoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2021-2032) Figure 17. Surgical Resection Image Figure 18. Ablation Image Figure 19. Liver Transplantation Image Figure 20. Global Hepatocellular Carcinoma Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Hepatocellular Carcinoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2021-2032) Figure 23. Global Hepatocellular Carcinoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Hepatocellular Carcinoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2032) Figure 40. China Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Hepatocellular Carcinoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Hepatocellular Carcinoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Hepatocellular Carcinoma Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Hepatocellular Carcinoma Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Hepatocellular Carcinoma Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Hepatocellular Carcinoma Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Hepatocellular Carcinoma Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Hepatocellular Carcinoma Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Hepatocellular Carcinoma Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Ablation Therapy
  • Brachytherapy
  • Chemotherapy
Applications
  • Surgical Resection
  • Ablation
  • Liver Transplantation
Companies covered
  • Teva Pharmaceutical
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Novartis
  • Sigma-Tau Group
  • Pacira
  • Luye Pharma
  • Kingond Pharm
  • Gilead Sciences
  • Fudan-Zhangjiang
  • CSPC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hepatocellular Carcinoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hepatocellular Carcinoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hepatocellular Carcinoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hepatocellular Carcinoma Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hepatocellular Carcinoma Drug Market Dynamics
  1. 2.1 Hepatocellular Carcinoma Drug Industry Trends
  2. 2.2 Hepatocellular Carcinoma Drug Industry Drivers
  3. 2.3 Hepatocellular Carcinoma Drug Industry Opportunities and Challenges
  4. 2.4 Hepatocellular Carcinoma Drug Industry Restraints
3 Hepatocellular Carcinoma Drug Market by Manufacturers
  1. 3.1 Global Hepatocellular Carcinoma Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hepatocellular Carcinoma Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hepatocellular Carcinoma Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hepatocellular Carcinoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatocellular Carcinoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hepatocellular Carcinoma Drug Manufacturers, Product Type & Application
  7. 3.7 Global Hepatocellular Carcinoma Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatocellular Carcinoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatocellular Carcinoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatocellular Carcinoma Drug Tier 1, Tier 2, and Tier 3
4 Hepatocellular Carcinoma Drug Market by Type
  1. 4.1 Hepatocellular Carcinoma Drug Type Introduction
  2. 4.1.1 Ablation Therapy
  3. 4.1.2 Brachytherapy
  4. 4.1.3 Chemotherapy
  5. 4.2 Global Hepatocellular Carcinoma Drug Sales by Type
  6. 4.2.1 Global Hepatocellular Carcinoma Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hepatocellular Carcinoma Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Hepatocellular Carcinoma Drug Revenue by Type
  10. 4.3.1 Global Hepatocellular Carcinoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hepatocellular Carcinoma Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2021-2032)
5 Hepatocellular Carcinoma Drug Market by Application
  1. 5.1 Hepatocellular Carcinoma Drug Application Introduction
  2. 5.1.1 Surgical Resection
  3. 5.1.2 Ablation
  4. 5.1.3 Liver Transplantation
  5. 5.2 Global Hepatocellular Carcinoma Drug Sales by Application
  6. 5.2.1 Global Hepatocellular Carcinoma Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatocellular Carcinoma Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hepatocellular Carcinoma Drug Revenue by Application
  10. 5.3.1 Global Hepatocellular Carcinoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatocellular Carcinoma Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2021-2032)
6 Global Hepatocellular Carcinoma Drug Sales by Region
  1. 6.1 Global Hepatocellular Carcinoma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatocellular Carcinoma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatocellular Carcinoma Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Hepatocellular Carcinoma Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hepatocellular Carcinoma Drug Revenue by Region
  1. 7.1 Global Hepatocellular Carcinoma Drug Revenue by Region
  2. 7.1.1 Global Hepatocellular Carcinoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hepatocellular Carcinoma Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Hepatocellular Carcinoma Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Hepatocellular Carcinoma Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hepatocellular Carcinoma Drug Revenue (2021-2032)
  8. 7.2.2 North America Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hepatocellular Carcinoma Drug Revenue (2021-2032)
  11. 7.3.2 Europe Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hepatocellular Carcinoma Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hepatocellular Carcinoma Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hepatocellular Carcinoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Hepatocellular Carcinoma Drug Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Hepatocellular Carcinoma Drug Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Sigma-Tau Group
  26. 8.5.1 Sigma-Tau Group Company Information
  27. 8.5.2 Sigma-Tau Group Business Overview
  28. 8.5.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Product Portfolio
  30. 8.5.5 Sigma-Tau Group Recent Developments
  31. 8.6 Pacira
  32. 8.6.1 Pacira Company Information
  33. 8.6.2 Pacira Business Overview
  34. 8.6.3 Pacira Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pacira Hepatocellular Carcinoma Drug Product Portfolio
  36. 8.6.5 Pacira Recent Developments
  37. 8.7 Luye Pharma
  38. 8.7.1 Luye Pharma Company Information
  39. 8.7.2 Luye Pharma Business Overview
  40. 8.7.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Luye Pharma Hepatocellular Carcinoma Drug Product Portfolio
  42. 8.7.5 Luye Pharma Recent Developments
  43. 8.8 Kingond Pharm
  44. 8.8.1 Kingond Pharm Company Information
  45. 8.8.2 Kingond Pharm Business Overview
  46. 8.8.3 Kingond Pharm Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kingond Pharm Hepatocellular Carcinoma Drug Product Portfolio
  48. 8.8.5 Kingond Pharm Recent Developments
  49. 8.9 Gilead Sciences
  50. 8.9.1 Gilead Sciences Company Information
  51. 8.9.2 Gilead Sciences Business Overview
  52. 8.9.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Gilead Sciences Hepatocellular Carcinoma Drug Product Portfolio
  54. 8.9.5 Gilead Sciences Recent Developments
  55. 8.10 Fudan-Zhangjiang
  56. 8.10.1 Fudan-Zhangjiang Company Information
  57. 8.10.2 Fudan-Zhangjiang Business Overview
  58. 8.10.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Portfolio
  60. 8.10.5 Fudan-Zhangjiang Recent Developments
  61. 8.11 CSPC
  62. 8.11.1 CSPC Company Information
  63. 8.11.2 CSPC Business Overview
  64. 8.11.3 CSPC Hepatocellular Carcinoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CSPC Hepatocellular Carcinoma Drug Product Portfolio
  66. 8.11.5 CSPC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatocellular Carcinoma Drug Value Chain Analysis
  2. 9.1.1 Hepatocellular Carcinoma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatocellular Carcinoma Drug Production Mode & Process
  6. 9.2 Hepatocellular Carcinoma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatocellular Carcinoma Drug Distributors
  9. 9.2.3 Hepatocellular Carcinoma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst